Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Omtryg side effects?

See the DrugPatentWatch profile for Omtryg

What are the side effects of Omtryg?

Omtryg is a biosimilar form of the anti-inflammatory medication omalizumab. It is used to treat severe asthma and chronic spontaneous urticaria (hives). Like other medications, Omtryg can cause side effects, some of which can be serious.

Common side effects of Omtryg **

According to the FDA, the most common side effects of Omtryg (incidence ≥ 5%) are: [1]
- Joint pain or swelling
- Allergic reactions (such as anaphylaxis, angioedema)
- Muscle pain
- Fever
- Increased risk of infections (e.g., upper respiratory tract infection, sinusitis)

**Less common side effects of Omtryg


Other potential side effects of Omtryg (incidence < 5%) include: [1]
- Thrombocytopenia (low platelet count)
- Eosinophilia (increased eosinophils in the blood)
- Lymphadenopathy (enlarged lymph nodes)
- Leukocytosis (increased white blood cells)

Rare but serious side effects of Omtryg

In rare cases, Omtryg can cause more serious side effects, such as:
- Anaphylaxis (a severe allergic reaction)
- Angioedema (rapid swelling of the skin)
- Stevens-Johnson syndrome (a life-threatening skin and mucous membrane disorder) [2]

Patient experiences and concerns

Patent concerns and experiences with Omtryg have been discussed online. Some patients report mild side effects like joint pain or muscle aches, while others experience more severe reactions. It's essential to consult with a healthcare provider if you have any concerns or questions about Omtryg. [3]

How should you manage side effects of Omtryg?

If you experience any side effects while taking Omtryg, it's crucial to inform your healthcare provider. They may recommend adjustments to your treatment plan or prescribe additional medications to help manage side effects.

Sources:
[1] FDA: Omtryg (omalizumab-abdn) Injection, for Subcutaneous Use, For Intravenous Use (December 2022)
[2] EMA (European Medicine Agency) - Omtryg - EPAR - Product Information (2022)
[3] Patient Reviews – Omtryg (omalizumab) | PatientsLikeMe



Other Questions About Omtryg :

Omtryg price? Is omtryg effective for high triglycerides?